Maxim resumed coverage of Xtant Medical (XTNT) with a Buy rating and $1.50 price target With the overall focus on the higher-growth and higher-margin orthobiologics business, Xtant is positioned for organic and profitable growth, and may engage in M&A, partnerships, or in-licensing deals, the analyst tells investors in a research note. Xtant is also currently self-financing and does not require a capital raise to continue operations, the firm added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XTNT:
- Xtant Medical Expands Portfolio with HEMOBLAST Distribution Deal
- Xtant Medical acquires U.S. distribution rights to Dilon’s Hemoblast Bellows
- Xtant Medical Warns of 2026 Profit Hit as One‑Time License Revenue and SimpliMax™ Reimbursements Fade
- Xtant Medical Earnings Call Highlights Profitability Turnaround
- Xtant Medical reports Q4 EPS 0c vs. (2c) last year